G1 Therapeutics, Inc. / Fundamentals

    Income statement

    Net revenue
    €49.64M
    Cost of goods sold
    €5.24M
    Gross profit
    €44.40M
    SG&A expenses
    €51.76M
    R&D expenses
    €24.95M
    EBITDA
    -€30.20M
    D&A
    €419.65K
    EBIT
    -€32.31M
    Interest expenses
    €7.63M
    EBT
    -€36.65M
    Tax expenses
    €1.61M
    Net income
    -€38.19M

    Cash flow statement

    Net deferred tax
    €498.12K
    Non-cash items
    €4.41M
    Changes in working capital
    -€4.25M
    Operating cash flow
    -€32.02M
    Capex
    €0.00
    Other investing cash flow
    -€379.56K
    Net investing cash flow
    €4.33M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €458.89K
    Debt repayment
    -€8.43M
    Other financing cash flow
    €996.25K
    Net financing cash flow
    -€7.19M
    Foreign exchange effects
    €0.00
    Net change in cash
    -€34.89M
    Cash at end of period
    €12.91M
    Free cash flow
    -€32.02M

    Balance sheet

    Cash and cash equivalents
    €12.91M
    Cash and short-term investments
    €51.85M
    Total receivables
    €11.35M
    Inventory
    €11.42M
    Other current assets
    €4.69M
    Total current assets
    €79.26M
    Property, plant & equipment
    €4.76M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €159.50K
    Other non-current assets
    €0.00
    Total non-current assets
    €4.92M
    Total assets
    €84.18M
    Accounts payable
    €4.40M
    Short-term debt
    €9.73M
    Other current liabilities
    €17.05M
    Total current liabilities
    €31.99M
    Long-term debt
    €31.18M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €34.97K
    Total non-current liabilities
    €31.21M
    Total liabilities
    €63.20M
    Common stock
    €4.26K
    Retained earnings
    -€678.67M
    Other equity
    €0.00
    Total equity
    €20.98M
    Total liabilities and shareholders' equity
    €84.18M

    Company information

    Market capitalization
    €322.20M
    Employees
    100
    Enterprise Value
    €410.58M

    Company ratios

    Gross margin
    89.4% Much worse than peer group: 1,126,961,787,785,738,600.0%
    EBITDA margin
    -60.9% Much better than peer group: -31,657,950,571,477,310,000.0%
    EBIT margin
    -65.1% Much better than peer group: -36,174,460,508,358,925,000.0%
    EBT margin
    -73.8% Much better than peer group: -34,918,756,397,134,074,000.0%
    Net margin
    -76.9% Much better than peer group: -34,967,534,544,524,060,000.0%
    ROE
    -182.1% Much worse than peer group: -59.7%
    ROA
    -45.4% Much better than peer group: -236.6%
    Asset turnover
    59.0% Much better than peer group: 19.4%
    FCF margin
    -64.5% Much better than peer group: -28,428,330,774,479,702,000.0%
    FCF yield
    -9.9%
    Efficiency ratio
    160.9%
    Net sales per employee
    €496.37K
    Net income per employee
    -€381.87K

    Notifications